2seventy bio Inc (TSVT)
4.705
-0.22
(-4.56%)
USD |
NASDAQ |
May 03, 15:31
2seventy bio Research and Development Expense (Annual): 230.76M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 230.76M |
| December 31, 2022 | 248.74M |
| December 31, 2021 | 252.62M |
| Date | Value |
|---|---|
| December 31, 2020 | 296.47M |
| December 31, 2019 | 297.64M |
| December 31, 2018 | 200.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
230.76M
Minimum
2023
297.64M
Maximum
2019
265.24M
Average
252.62M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Bristol-Myers Squibb Co | 9.299B |
| Johnson & Johnson | 15.08B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Macrogenics Inc | 166.58M |
| Akebia Therapeutics Inc | 63.08M |